{"id":266154,"date":"2026-09-24T09:56:53","date_gmt":"2026-09-24T04:26:53","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=266154"},"modified":"2026-09-24T09:56:53","modified_gmt":"2026-09-24T04:26:53","slug":"piramal-pharma-vs-sai-life-sciences-vs-neuland-labs","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/piramal-pharma-vs-sai-life-sciences-vs-neuland-labs\/","title":{"rendered":"Piramal Pharma vs Sai Life Sciences vs Neuland Laboratories: Which Stock Should You Track"},"content":{"rendered":"

Piramal Pharma PE NA, mkt cap Rs 28,045 crore. Sai Life Sciences PE 94.54, mkt cap Rs 34,201 crore. Neuland Laboratories PE 57.98, mkt cap Rs 28,859 crore.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Piramal Pharma vs Sai Life Sciences vs Neuland Laboratories is a side-by-side comparison of three companies from the CRAMS and Pharma CDMO space. On this comparison, Piramal Pharma carries a market capitalisation of about Rs 28,045 crore against Rs 34,201 crore for Sai Life Sciences and Rs 28,859 crore for Neuland Laboratories, with return on equity of -3.58%, 14.05% and 19.42% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.<\/p>\n<\/div>\n

Piramal Pharma vs Sai Life Sciences vs Neuland Laboratories starts with the core numbers most investors compare within the CRAMS and Pharma CDMO segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.<\/p>\n

All three names sit in the CRAMS and Pharma CDMO bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n